Bd reports fourth quarter and full year fiscal 2022 financial results

Execution of bd 2025 strategy driving consistent durable growth q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and increased 2.3% on a currency-neutral basis q4 revenue performance driven by base revenue growth of 4.2% as reported, 8.6% currency-neutral q4 gaap and adjusted diluted eps from continuing operations of $0.92 and $2.75, respectively fy22 revenue from continuing operations of $18.9 billion decreased 1.4% as reported and increased 0.9% on a currency-neutral basis fy22 revenue performance driven by base revenue growth of 6.9% as reported, 9.4% currency-neutral fy22 gaap and adjusted diluted eps from continuing operations of $5.38 and $11.35, respectively company issues fy23 guidance; announces 51st consecutive year of dividend increases, dividend raised 4.6% franklin lakes, n.j. , nov. 10, 2022  /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced results for its fourth quarter and full year of fiscal 2022, which ended september 30, 2022.
BDX Ratings Summary
BDX Quant Ranking